Oncology

Views & Analysis

ASCO 2017: Breast cancer next target for Keytruda

Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.

Views & Analysis

The cancer challenge: the quest for a cure is only half the ...

The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.

Views & Analysis

Deep Dive: Oncology magazine launched today

Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?

News

Regeneron and Inovio to aim immunotherapy at hard-to-treat b...

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour.

Views & Analysis

Non-profit model for childhood cancer drugs

Charities must work to help pharma and academia prioritise and accelerate paediatric treatments.

News

NICE rejects Opdivo in head and neck cancer – before it gain...

England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro

ASCO 2017: Breast cancer next target for Keytruda

The cancer challenge: the quest for a cure is only half the ...

Deep Dive: Oncology magazine launched today

Regeneron and Inovio to aim immunotherapy at hard-to-treat b...

Non-profit model for childhood cancer drugs

NICE rejects Opdivo in head and neck cancer – before it gain...

uniQure falls on long-term Huntington's gene therapy data

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks